Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares traded down 4.4% during trading on Wednesday . The company traded as low as $18.37 and last traded at $18.59, with a volume of 217,278 shares trading hands. The stock had previously closed at $19.45.

A number of research analysts recently commented on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $22.00 price target on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 11th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $21.00 price target for the company in a research note on Wednesday, August 10th. Jefferies Group boosted their price target on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. BMO Capital Markets reaffirmed a “hold” rating and issued a $17.00 price target on shares of Amphastar Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $19.83.

The firm has a market capitalization of $857.30 million and a PE ratio of 61.69. The company has a 50-day moving average of $17.78 and a 200 day moving average of $14.58.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.22. During the same period last year, the business earned ($0.09) earnings per share. The business had revenue of $68 million for the quarter, compared to analysts’ expectations of $62.10 million. The company’s revenue for the quarter was up 26.4% on a year-over-year basis. On average, analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.37 EPS for the current year.

In related news, Director Stephen B. Shohet sold 48,375 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $18.24, for a total transaction of $882,360.00. Following the sale, the director now owns 28,653 shares in the company, valued at $522,630.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 2,297 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $16.00, for a total transaction of $36,752.00. Following the sale, the chief financial officer now owns 66,949 shares in the company, valued at approximately $1,071,184. The disclosure for this sale can be found here.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.